We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Giant Cell Arteritis

News List

Final NHS nod for Roche’s RoActemra pharmatimes
July 16, 2018
Roche/Chugai’s RoActemra should be routinely offered throughout the NHS to adults with giant cell arteritis (GCA) within the next three months, following a final green light from cost regulators.
European Commission approves Roche’s tocilizumab to treat giant cell arteritis pharmaceufical-technology
September 26, 2017
Roche’s Actemra / RoActemra (tocilizumab) has received approval from the European Commission (EC) to treat giant cell arteritis (GCA).
US FDA accepts Genentech Actemra’s sBLA for Giant Cell Arteritis pharmaceutical-technology
January 26, 2017
The US Food and Drug Administration (FDA) has accepted Genentech’s supplemental biologics licence application (sBLA) for Actemra (tocilizumab) for the treatment of Giant Cell Arteritis (GCA).